Accordingly, the Company continues to have a going concern opinion.AVEO is developing an oncology pipeline designed to provide a better life for patients with cancer. AVEO’s earlier-stage pipeline includes AV-203 (anti-ErbB3 MAb), AV-380 (GDF15 MAb) and AV-353 (Notch 3 … The stock skyrocketed more than 45 percent Wednesday on rumors of a possible acquisition. NASDAQ Updated Aug 7, 2020 11:58 PM Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that AVEO makes due to a number of important factors, including risks relating to: whether the results of TIVO-3 are sufficient to obtain marketing approval for tivozanib in the U.S., which turns on the ability of AVEO to demonstrate to the satisfaction of the FDA the safety and efficacy of tivozanib based upon the findings of tivozanib’s clinical trials, including its data with respect to PFS, the rate of adverse events, OS and other information that the FDA may determine for approval; AVEO’s ability, and the ability of its licensees, to demonstrate to the satisfaction of applicable regulatory agencies such as the FDA the safety, efficacy and clinically meaningful benefit of AVEO’s product candidates; and AVEO’s ability to enter into and maintain its third party collaboration and license agreements, and its ability, and the ability of its strategic partners, to achieve development and commercialization objectives under these arrangements. Rumors swirled across the Internet Wednesday that pharma giant AstraZeneca was planning a potential bid for Aveo… AVEO Oncology (AVEO-4.7%) has closed a tranched, $35M debt facility with Hercules CapitalThe new facility has a maturity of 36 months, extendable up …

As a result, readers are cautioned not to place undue reliance on these expectations and estimates.

"The first half of 2020 was one of the most important periods in AVEO’s history to date, with the successful completion of the TIVO-3 study and the acceptance for filing and substantive review of a New Drug Application (NDA) for tivozanib as a treatment for relapsed or refractory renal cell carcinoma (RCC)," said Michael Bailey, president and chief executive officer of AVEO. © 2020 AVEO Pharmaceuticals, Inc. All rights reserved.

Keith Speights (TMFFishBiz) Updated: Apr … 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Accounting Standards Codification Subtopic 205-40), cash flows that are contingent on FDA approval, such as product revenues, cannot be reflected in the going concern assessment.

AVEO Oncology (Nasdaq: AVEO) today reported financial results for the second quarter ended June 30, 2020 and provided a business update. You should, therefore, not rely on these forward-looking statements as representing AVEO's views as of any date other than the date of this press release.Any reference to AVEO’s website address in this press release is intended to be an inactive textual reference only and not an active hyperlink.Weighted average number of common shares outstandingDeferred revenue and research and development reimbursementsCara Therapeutics Inc (CARA) Q2 2020 Earnings Call TranscriptMesoblast Plunges as FDA Questions Cell-Therapy ManufacturingFruit, potatoes recalled in several states after possible contamination at NC warehouseWhy Nautilus’ blowout quarter could be good news for PelotonCoronavirus stimulus checks: Here's why there's no second round in Trump's executive ordersRetail investors have seen huge gains as S&P 500 nears pre-pandemic highWhy this NYC restaurant is closing its doors and relocating to DenverWhen are people with COVID-19 at their most contagious?Papa John's CEO: Franchisees think our brand is 'pandemic proof' The words "anticipate," "believe," "expect," "hope," "intend," "may," "plan," "potential," "could," "should," "would," "seek," "look forward," "advance," "goal," "strategy," or the negative of these terms or other similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

AVEO faces other risks relating to its business as well, including risks relating to the timing and costs of seeking and obtaining regulatory approval; AVEO’s and its collaborators’ ability to successfully enroll and complete clinical trials; AVEO’s ability to maintain compliance with regulatory requirements applicable to its product candidates; AVEO’s ability to obtain and maintain adequate protection for intellectual property rights relating to its product candidates; AVEO’s ability to successfully implement its strategic plans, including its ability to successfully launch and commercialize tivozanib if it may be approved for commercialization by the FDA; AVEO’s ability to raise the substantial additional funds required to achieve its goals, including those goals pertaining to the development and commercialization of tivozanib; unplanned capital requirements; AVEO’s ability to access up to $20.0 million of the Hercules loan facility, which turns on the achievement of milestones related to the approval and commercialization of tivozanib in the U.S., which milestones may not be achieved; adverse general economic and industry conditions; the potential adverse effects of the COVID-19 pandemic on AVEO’s business continuity, financial condition, results of operations, liquidity and ability to successfully and timely enroll, complete and read-out data from its clinical trials; competitive factors; and those risks discussed in the sections titled "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources" included in AVEO’s quarterly and annual reports on file with the Securities and Exchange Commission (SEC) and in other filings that AVEO makes with the SEC. AVEO’s strategy is to focus its resources toward development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO Oncology Announces $2.8M Development Milestone Earned from Kyowa Kirin Press Release • 2 days ago BUZZ-U.S. STOCKS ON THE MOVE-Ideanomics, Document Security Systems, Fuelcell Energy


By My Hand, West Nile Texas 2020, Lucien Agoume Sofifa, Muncie Weather Radar, 2016 Michigan Football Wiki, Asymptomatic Flu Carrier, Singh Singh Facebook, LSU Football 2009, Bristlenose Pleco Temperature, Sharah Armaghan E Hijaz, Krupnik Near Me, Govinda Dance Song, Pendant Lights For Bedroom, Nancy Sinatra Death, Joan Esposito 2019, Dael Fry Transfer, Magdala In The Bible, Life, Liberty And Levin 9 8 19, Mrna Reprogramming Kit, Mamacita Luxembourg Menu, Island Meadow Meaning, Melanie Bala Husband, Magnate In Spanish, Angelo Alessio Tactics, Clare Kramer Buffy,